SCHEMBL5652915

SCHEMBL5652915

COc1ccc(CSC(C)(C)c2ccc(C(N)=O)c(C3=CCC(C)(C)CC3)c2)cc1

nearest known ligand 0.59

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
CSF1R P07333 14/20 0.59
IDO1 P14902 2/20 0.36
KIT P10721 7/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5652918 0.87 CSF1R (0.58) CSF1RIDO1KIT
SCHEMBL4343760 0.79 CSF1R (0.52) CSF1RKIT
SCHEMBL3084355 0.77 CSF1R (0.50) CSF1RKIT
SCHEMBL14383378 0.77 CSF1R (0.72) CSF1RKIT
SCHEMBL4188947 0.75 CSF1R (0.40) CSF1RKIT
SCHEMBL5652718 0.74 CSF1R (0.59) CSF1RKIT
Hydrochloric Acid SCHEMBL5652306 0.74 CSF1R (0.59) CSF1RKIT
SCHEMBL15418403 0.73 CSF1R (0.58) CSF1RKIT
SCHEMBL15418703 0.73 CSF1R (0.60) CSF1RKIT
SCHEMBL4183963 0.72 KIT (0.56) CSF1RKIT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9452996-B2 Inhibitors of c-fms kinase JANSSEN PHARMACEUTICA NV (BE) 2016-09-27 US disclosed
US-20160046602-A1 INHIBITORS OF C-FMS KINASE JANSSEN PHARMACEUTICA NV (BE) 2016-02-18 US disclosed
US-9221797-B2 Inhibitors of c-fms kinase JANSSEN PHARMACEUTICA NV (BE) 2015-12-29 US disclosed
US-20140148448-A1 INHIBITORS OF C-FMS KINASE JANSSEN PHARMACEUTICA NV (BE) 2014-05-29 US disclosed
US-8674100-B2 Inhibitors of C-FMS kinase JANSSEN PHARMACEUTICA, N.V. (BE) 2014-03-18 US disclosed
EP-2687516-A1 Inhibitors of C-FMS Kinase Janssen Pharmaceutica N.V. (BE) 2014-01-22 EP disclosed
US-20070249649-A1 INHIBITORS OF C-FMS KINASE JANSSEN PHARMACEUTICA, N.V. (BE) 2007-10-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070249649-A1 INHIBITORS OF C-FMS KINASE FES, MUSK, FRK CSF1R 58/4885IDO1 2767/4885KIT 114/4885
US-20140148448-A1 INHIBITORS OF C-FMS KINASE FES, MUSK, FRK CSF1R 58/4885IDO1 2767/4885KIT 114/4885
US-20160046602-A1 INHIBITORS OF C-FMS KINASE FES, MUSK, FRK CSF1R 58/4885IDO1 2767/4885KIT 114/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.